{"prompt": "['Alliance A171601', 'For Patients with Non-Measurable Disease Only', 'Non-Target Lesions &', 'New', 'Overall', 'Non-Target Lymph Nodes', 'Sites of Disease', 'Objective Status', 'CR', 'No', 'CR', 'Non-CR/Non-PD', 'No', 'Non-CR/Non-PD', 'Not All Evaluated*', 'No', 'Not Evaluated (NE)', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', '*', 'See Section 11.5.3', '11.5.5 Symptomatic Deterioration', 'Patients with global deterioration of health status requiring discontinuation of treatment', 'without objective evidence of disease progression at that time, and not either related to study', 'treatment or other medical conditions, should be reported as PD due to \"symptomatic', 'deterioration.\" Every effort should be made to document the objective progression even', 'after discontinuation of treatment due to symptomatic deterioration.', '11.6 Definitions of Analysis Variables', 'Formal definitions of variables used in analyses can be found in the Statistical Considerations', 'section of the protocol.', '12.0', 'END OF TREATMENT/INTERVENTION', '12.1 Duration of Treatment', 'Patients should continue protocol treatment until disease progression or unacceptable toxicity.', 'There are no minimum required cycles of therapy.', '12.2 Follow-up for patients who discontinue protocol therapy', '12.2.1 Disease Progression', 'Remove from protocol therapy any patient with disease progression. Document details,', 'including tumor measurements, on data forms.', 'After disease progression, patients should be followed for survival every year per the study', 'calendar (Section 5.0).', '12.2.2 Unacceptable toxicity', 'Patients who discontinue treatment for unacceptable toxicities should continue to be', 'followed for progression. Following progression, patients will be followed every year for', 'survival.', 'In', 'addition, patients who discontinue therapy within 1 year after registration will be', 'followed for toxicity outcomes for an additional 30 days after stopping the drug and until', 'resolution of all grade >2 toxicities. Resolution or stabilization of the adverse event will be', 'recorded even if disease progression has occurred.', '56', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '12.2.3 Other reasons for discontinuation of protocol therapy', 'Patients who discontinue treatment for any other reason than progression or unacceptable', 'toxicity should continue to be followed for progression. Following progression, patients will', 'be followed every year for survival. The reason for disc ontinuation of protocol treatment', 'must be documented on the \"Off treatment\" form.', '12.2.4 Discontinuation of Geriatric Assessment and Specimen Submission', 'Geriatric Assessment: Patients will complete the geriatric assessment at the end of', 'treatment. If end of treatment occurs prior to the end of Cycle 3, the end of cycle 3', 'assessment need not be submitted. (That is, patients who discontinue protocol treatment', 'prior to the end of cycle 3 will have completed a geriatric assessment at baseline and at the', 'end of treatment.)', 'Specimen Submission: Patients who discontinue protocol treatment prior to the end of', 'Cycle 3 must still be asked to submit an end of treatment blood sample rather than the prior', 'to Cycle 4 blood sample listed in Section 6.2.', '12.3 Managing ineligible patients and registered patients who never receive protocol', 'intervention', 'Definition of ineligible patient', 'A study participant who is registered to the trial but does not meet all of the eligibility criteria', 'is deemed to be ineligible.', 'Follow-up for ineligible patients who continue with protocol treatment', 'Patients who are deemed ineligible after registering may continue protocol treatment, provided', 'the treating physician, study chair, and executive officer agree there are no safety concerns if', 'the patient continues protoco treatment. All scans, tests, and data submission are to continue as', 'if the patient were eligible. Notification of the local IRB may be necessary per local IRB', 'policies.', 'Follow-up for ineligible patients who discontinue protocol treatment', 'For patients who are deemed ineligible after registering to the trial, who start treatment, but then', 'discontinue study treatment, the same data submission requirements are to be followed as for', 'those patients who are eligible and who discontinue study treatment.', 'Follow-up for patients who are registered but who never start study treatment', 'For all study participants who are registered to the trial but who never receive study intervention', '(regardless of eligibility), the follow-up requirements are specified below.', 'Baseline and off-treatment notice data submission required. See the Data Submission Schedule', 'accompanying the All Forms Packet.', '12.4 Extraordinary Medical Circumstances', \"If, at any time the constraints of this protocol are detrimental to the patient's health and/or the\", 'patient no longer wishes to continue protocol therapy, protocol therapy shall be discontinued In', 'this event:', 'Document the reason(s) for discontinuation of therapy on data forms.', 'Follow the patient for protocol endpoints as required by the Study Calendar.', '57', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}